PA-CENCORA
14.5.2024 15:36:33 CEST | Business Wire | Press release
Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.
The two-day virtual event, which kicks off May 14, will feature panel discussions and presentations that cover key topics and considerations across the commercialization journey — from clinical manufacturing and channel strategy to the solutions needed to support efficient global launches, navigate the unique supply chain requirements, and overcome barriers along the patient journey. The event will feature perspectives from a wide range of leaders, including experts from companies that have launched or are developing a CGT as well as representatives from patient advocacy groups, trade associations, and the U.S. Food and Drug Administration (FDA).
“We are entering a new era in cell and gene therapy — with new modalities reaching the market and a growing number of products in clinical development, including therapies that target larger patient populations. However, the path to commercialization is complex and lined with potential challenges that can impact product success and patient access,” said Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at Cencora. “By bringing together this group, our goal is to foster collaboration and advance best practices that will support the development and commercialization of these groundbreaking therapies and help to ensure they can reach the patients who need them.”
There are nearly 2,000 CGT clinical trials underway globally, according to the Alliance for Regenerative Medicine (ARM). In the United States and Europe, there could be as many as 17 regulatory decisions on CGTs in 2024.
During Cencora’s summit, industry experts will examine strategies to overcome barriers at each stage of the product lifecycle — from research and clinical development (R&D) to global commercialization and patient engagement strategies. The event will be capped by a fireside chat with ARM’s Chief Operating Officer Rita Johnson-Greene, who will reflect on the progress seen in the last five years and offer her perspective on what she expects will happen during the next half-decade.
A leader in specialty distribution and services, Cencora offers CGT developers support at each stage of the product lifecycle, including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution, and patient support services. Through its CGT Integration Hub, Cencora connects provider-facing platforms with patient services support programs to increase visibility across the therapy development and delivery process, streamlining the path-to-care.
“We believe the next five years hold tremendous promise for this market and patients worldwide, and we continue to invest in solutions to elevate the support we offer to developers to help them bring their products to market,” said Willis Chandler, President of Global Pharma Services at Cencora. “Launching this summit reflects our belief in the promise of cell and gene therapies, as well as our commitment to create a more connected CGT ecosystem and unlock the potential of these therapies.”
For more information or to register for the event, visit: https://www.cencora.com/campaign/gps/thinklive-2024-cgt-summit.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508817695/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 08:14:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer12.6.2026 08:00:00 CEST | Press release
Kazuhiko Nakayama appointed President and CEO of NTT DATA Group; Yutaka Sasaki to become Senior Executive Vice President of NTT, Inc. NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18. Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates. NTT DATA Group’s growth strategy will focus on two key areas alongside its core b
Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes11.6.2026 23:00:00 CEST | Press release
Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption. The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amount
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom